The HealthTech Signal
Chai Discovery triples its valuation as pharma buys into AI-designed molecules
Chai Discovery triples its valuation as pharma buys into AI-designed molecules
Dr. Dereck Mush, MD, MBA
LabGenius
Uses machine learning and robotic automation to discover novel protein therapeutics.
What they do
LabGenius operates an automated, closed-loop discovery platform that designs, conducts, and learns from its own wet-lab experiments. Pharmaceutical partners use this system to optimize protein-based therapeutics, specifically engineered antibodies for oncology and inflammatory diseases.
The record
- Vertical
- Pharma & Drug Discovery
- Sub-segment
- Protein design
- Product type
- Service
- Stage
- Series B
- Headquarters
- London, UK
- Region
- Europe
- Founded
- 2012
- Total funding
- $43M raised
Notable investors: Atomico, Lux Capital, Obvious Ventures, Octopus Ventures.
Also in Pharma & Drug Discovery
Related on The Signal
Dr. Dereck Mush, MD, MBA
Bypassing Carrier Suppression: The 31-Valent Conjugate Architecture Reshaping Pneumococcal Vaccinology
Dr. Dereck Mush, MD, MBA
AI is moving upstream, from molecule design into disease target identification itself
Dr. Dereck Mush, MD, MBA
What Pharma Is Buying From AI Drug Discovery: Inside AstraZeneca’s insitro Deal
Dr. Dereck Mush, MD, MBA